TherapeuticsMD, Inc. (TXMD)
Company Info
US88338N1072
88338N107
Dec 11, 2003
Highlights
$16.44M
-$0.20
-0.73
$2.12M
$2.12M
-$3.29M
$0.70 - $2.25
$5.00
1.72%
3.23
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in TherapeuticsMD, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
TherapeuticsMD, Inc. (TXMD) returned 62.79% year-to-date (YTD) and -31.03% over the past 12 months. Over the past 10 years, TXMD returned -41.66% annually, underperforming the S&P 500 benchmark at 10.43%.
TXMD
62.79%
59.09%
-7.89%
-31.03%
-53.48%
-41.66%
^GSPC (Benchmark)
-3.70%
13.67%
-5.18%
9.18%
14.14%
10.43%
Monthly Returns
The table below presents the monthly returns of TXMD, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 25.58% | -13.89% | -0.54% | 34.05% | 12.90% | 62.79% | |||||||
| 2024 | 0.44% | 6.19% | -4.58% | -17.90% | 18.09% | -27.48% | 8.70% | 7.71% | -11.94% | -6.63% | -8.39% | -39.44% | -61.78% |
| 2023 | -5.72% | -5.88% | -24.40% | -5.60% | 17.23% | -0.72% | -1.46% | -6.65% | -20.32% | -29.47% | 21.13% | -12.79% | -59.75% |
| 2022 | -14.63% | -21.19% | 58.86% | -46.92% | -1.54% | 0.20% | -37.39% | 59.07% | -33.00% | -4.67% | -27.65% | 22.05% | -68.55% |
| 2021 | 36.36% | -7.88% | -11.84% | -9.70% | 0.00% | -1.65% | -15.97% | -20.50% | -6.74% | -1.81% | -32.01% | -28.18% | -70.62% |
| 2020 | -7.02% | -24.89% | -37.28% | 49.06% | -28.48% | 10.62% | 48.00% | -21.08% | 8.22% | -22.78% | 9.84% | -9.70% | -50.00% |
| 2019 | 37.80% | 8.95% | -14.86% | -11.70% | -28.84% | -15.03% | -17.31% | 34.42% | 25.61% | -26.72% | -5.64% | -3.59% | -36.48% |
| 2018 | -2.65% | -14.97% | -2.60% | 12.94% | 7.45% | 5.58% | -16.35% | 24.14% | 1.23% | -25.46% | 2.86% | -24.25% | -36.92% |
| 2017 | 0.69% | 8.09% | 14.65% | -29.17% | -18.63% | 26.99% | 7.21% | 6.19% | -11.83% | -10.78% | 33.47% | -4.13% | 4.68% |
| 2016 | -31.05% | -14.55% | 4.75% | 28.91% | 8.36% | -4.92% | -8.59% | -11.45% | -1.02% | -15.71% | 3.48% | -2.86% | -44.36% |
| 2015 | -8.76% | 24.88% | 19.33% | 7.11% | 9.26% | 11.02% | -0.89% | -21.31% | -4.40% | 0.17% | 27.94% | 38.08% | 133.03% |
| 2014 | 26.30% | 4.41% | -8.15% | -33.44% | -3.33% | 8.87% | 4.98% | 19.61% | -16.40% | -4.31% | -13.51% | 15.89% | -14.59% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of TXMD is 40, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for TherapeuticsMD, Inc. (TXMD) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the TherapeuticsMD, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the TherapeuticsMD, Inc. was 99.99%, occurring on Mar 14, 2025. The portfolio has not yet recovered.
The current TherapeuticsMD, Inc. drawdown is 99.98%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.99% | Feb 3, 2010 | 3484 | Mar 14, 2025 | — | — | — |
| -86.67% | Aug 24, 2009 | 1 | Aug 24, 2009 | 50 | Dec 8, 2009 | 51 |
| -53.64% | Feb 26, 2009 | 4 | Jun 15, 2009 | 3 | Jul 21, 2009 | 7 |
| -37.11% | Jan 25, 2010 | 2 | Jan 26, 2010 | 5 | Feb 2, 2010 | 7 |
| -29.03% | Dec 15, 2009 | 10 | Dec 30, 2009 | 10 | Jan 22, 2010 | 20 |
Volatility
Volatility Chart
The current TherapeuticsMD, Inc. volatility is 21.24%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
The chart below illustrates the trends in the financial health of TherapeuticsMD, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of TherapeuticsMD, Inc., comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -355.3%.
Valuation
The Valuation section provides an overview of how TherapeuticsMD, Inc. is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for TXMD compared to other companies in the Drug Manufacturers - Specialty & Generic industry. TXMD currently has a PEG ratio of -0.7. This PEG ratio is negative, which typically signals that the company's earnings are expected to decline. A negative PEG is not considered meaningful for valuation purposes.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for TXMD relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, TXMD has a P/S ratio of 9.4. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for TXMD in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, TXMD has a P/B value of 0.6. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |